Table 4.
Results of multiple regression for the decrease in sclerostin or FGF-23 posttreatment in the calcitriol group
| PTH | UA | Cr | ALP | Urinary Ca | Grip strength (left) | |
|---|---|---|---|---|---|---|
|
| ||||||
| SOST | ||||||
| B | 2.07 | 1.75 | 1.18 | 1.83 | 0.96 | 0.54 |
| OR (95% CI) for decrease in SOST | 7.90 (2.28–27.42) | |||||
| P-value | 0.001 | 0.13 | 0.17 | 0.17 | 0.33 | 0.46 |
|
| ||||||
| FGF-23 | ||||||
| B | −0.03 | −0.13 | −0.35 | 0.13 | −5.16 | 0.13 |
| P-value | 0.76 | 0.24 | 0.37 | 0.21 | 0.67 | 0.20 |
Notes: Decreases in FGF-23 are defined as having change from baseline ≤0. Decreases in SOST are defined as having change from baseline ≤0.
Abbreviations: Cr, creatinine; FGF-23, fibroblast growth factor-23; Grip (left), grip strength of left hand; PTH, parathyroid hormone; SOST, sclerostin; UA, serum uric acid; Urinary Ca, 24-hour urinary calcium.